| Entries |
| Document | Title | Date |
|---|
| 20080200553 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM - Pentafluorosulfanylbenzoylguanidines of the formula I and II | 08-21-2008 |
| 20090054528 | Bridged polycyclic compound based compositions for coating oral surfaces in pets - A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be applied to an oral surface of an animal (e.g., canine, feline) such that an oral malady may be inhibited and/or ameliorated. | 02-26-2009 |
| 20090069435 | Bridged polycyclic compound based compositions for topical applications for pets - A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be applied to an topical surface and/or an otic surface of an animal (e.g., canine, feline) such that an topical malady and/or otic malady may be inhibited and/or ameliorated. | 03-12-2009 |
| 20090275663 | Method for Producing a Disinfecting Agent - The invention relates to medicine, in particular to sanitary and hygiene, more specifically to methods for producing a disinfecting agent for decontaminating different types of water, including drinking water. The inventive disinfecting agent producing method by dissolving quaternary ammonium compounds in water in the presence of an active additive in the form of guanidines, consists in preparing an aqueous 1-15% guanidine solution by permanently agitating it at a temperature ranging from 30 to 90° C., in cooling the solution accompanied with a precipitation control, when the precipitation process is over, in filtering the solution by using a filter whose cell size ranges from 10 to 1 mkm and in adding the quaternary ammonium compounds into the solution in such away that the concentration thereof in said solution is equal to 0.1-3%. | 11-05-2009 |
| 20100056641 | Novel Aminoguanidines as Melanocortin Receptor Ligands - There are described compounds of general formula (I) and isomeric forms thereof wherein n is 0, 1, 2 or 3, saturated or unsaturated; most preferably at least one of R | 03-04-2010 |
| 20100160445 | Synergistic Mixtures of OPP and DGH - Ortho phenylphenol or its sodium salt is shown to form synergistic antimicrobial mixtures with nitrogen and aldehyde-containing microbiocides. | 06-24-2010 |
| 20100173996 | SYNERGISTIC MIXTURES OF OPP AND DGH - Ortho phenylphenol or its sodium salt is shown to form synergistic antimicrobial mixtures with nitrogen and aldehyde-containing microbiocides. | 07-08-2010 |
| 20100222433 | Composite Disinfectant Cleaner - A disinfectant cleaner is provided by combining an alkyl dimethyl benzyl ammonium chloride, an octyl decyl dimethyl ammonium chloride, a dioctyl dimethyl ammonium chloride, a didecyl dimethyl ammonium chloride, an alkylamine, a guanidine, a penetrant, a surfactant, a chelant, an essence and deionized water. | 09-02-2010 |
| 20110060051 | PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION - The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyI)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of β-cell compensation. | 03-10-2011 |
| 20110092601 | LYSINE-SPECIFIC DEMETHYLASE INHIBITORS - Polyamine, polyamine/guanidino, and polyamine/biguanide compounds bearing allene, propargyl, cyclopropyl, and other reactive moieties are disclosed. The compounds are useful as irreversible inhibitors of the enzyme lysine-specific demethylase-1 and for the treatment of cancer. | 04-21-2011 |
| 20110184070 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF - Novel compounds of the following formula (I): | 07-28-2011 |
| 20110201688 | N,N'-DI-P-BROMOPHENYL GUANIDINE TREATMENT FOR STROKE AT DELAYED TIMEPOINTS - 1,3 di-o-tolylguanidine (DTG) was examined as anti-stroke drug with a broad therapeutic window. DTG activates sigma 1 and 2 receptors. Administration of DTG at 24 hours post-stroke to rats reduces neurodegeneration by 85%; this is the only pharmacological agent that has been used successfully at this delayed timepoint. Treatment with DTG provides protection of neurons exposed to hypoxia and blocks activation of immune cells that are responsible for delayed neurodegeneration associated with stroke. Disclosed is an altered DTG structure, placing a bromide at the para position to increase tissue penetrance and efficacy. Results show that N,N′-di-p-bromophenyl guanidine protects cultured neurons under hypoxic conditions but is more potent than DTG. Moreover, N,N′-di-p-bromophenyl guanidine is as least as efficacious as DTG in treating rats 24 hours after experimental stroke. | 08-18-2011 |
| 20120035268 | SPHINGO-GUANIDINES AND THEIR USE AS INHIBITORS OF SPHINGOSINE KINASE - The presently disclosed subject matter provides compounds of the formula: (1) and pharmaceutically acceptable salts thereof, wherein R | 02-09-2012 |
| 20120136062 | NOVEL COMPLEX FOR TREATMENT AND/OR PROPHYLAXIS OF PARASITIC INFECTIONS - Disclosed are complexes of an antipneumocystic compound and an antimalarial compound, processes for their preparation, pharmaceutical compositions and methods of using said complexes or compositions for the treatment and/or prophylaxis of parasitic infections. | 05-31-2012 |
| 20120202887 | Facially Amphiphilic Polyaryl and Polyarylalkynyl Polymers and Oligomers and Uses Thereof - The present invention discloses methods of use of facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers, including, but not limited to, pharmaceutical uses of the polymers and oligomers as antimicrobial agents and as antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers, compositions of the novel polymers and oligomers, including pharmaceutical compositions, and methods of designing and synthesizing the facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers. | 08-09-2012 |
| 20140066517 | USE OF CALIXARENES ASSOCIATED WITH AN ANTIBOTIC IN THE TREATMENT OF BACTERIAL INFECTIONS - A product comprising a calixarene for its use in the treatment of pathologies involving at least one bacterial strain having a resistance to at least one defined antibiotic, on patients undergoing simultaneous or sequential treatment with a given antibiotic to which said bacterial strain optionally has a resistance. | 03-06-2014 |
| 20140088198 | AGROCHEMICAL FORMULATIONS CONTAINING A COMPATIBILITY AGENT - Agrochemical compositions are described which contain a carboxylic acid salt of dodecylguanidine and a compatibility agent for slowing down the dissociation reaction of the carboxylic acid salt of dodecylguanidine in an aqueous medium. Also, the formation of anionic dodecylguanidine is suppressed or prevented. The ratio of the dodecylguanidine acetate to that of the compatibility agent in the agricultural compositions is below 5.0, preferably between 3.0 and 0.5, more preferably equals 1.4. | 03-27-2014 |
| 20140364505 | LYTIC AGENTS FOR USE IN TREATING INTRAVASCULAR CLOTS - Agents and methods are provided for breaking down and/or assisting in the removal of clots, in embodiments chronic clots, from the vasculature. In embodiments, the agents and methods may be used in the vasculature, in particular the peripheral venous vasculature, in order to prevent clot formation and/or lyse clots in patients suffering from complications, such as thrombosis, or from conditions, such as deep vein thrombosis (DVT). | 12-11-2014 |
| 20150051291 | N,N'-DI-1 NAPHTHYLGUANIDINE HCL (NAGH) AND N,N'-DI-P-NITROPHENYLGUANIDINE HCL (NAD) TREATMENT FOR STROKE AT DELAYED TIMEPOINTS - A composition and method of treating stroke by administration of a novel sigma agonist is presented. Twenty-four hours after MCAO, systemic administration of several novel sigma agonists including: Bromo-DTG; Chloro-DTG; N,N′-di-1-Naphthylguanidine hydrochloride (NAGH); N,N′-di-p-Nitrophenylguanidine HCL (NAD) or vehicle were injected subcutaneously daily for 3 days. Rats treated with Bromo-DTG and Chloro-DTG had no significant improvements in any of the motor or cognitive tests while NAGH treated rats showed improved vertical movement and had significantly less motor asymmetry and bias than vehicle treated rats. Sigma receptor agonist NAGH also was found to exert its long-term neuroprotective effects by preserving both gray matter and white matter tracts. Both NAD and NAGH, when administered 24 hours after experimental stroke, reduced neural damage and enhanced behavioral recovery thirty days later which suggests that NAGH and NAD potentially extend the therapeutic window of stroke several fold over the current treatments. | 02-19-2015 |
| 20150368193 | BIOACTIVE POLYMERS - Polycondensation products of aminoguanidine and/or 1,3-diaminoguanidine with one or more diamines are provided including polyguanidine derivatives of the following formula (I) or a salt thereof: | 12-24-2015 |
| 20160018407 | METABOLIC PROFILES - The invention relates to the use of endogenous metabolites to produce a metabolic profile of a disorder or disease in a subject, e.g. an autoimmune disease, in particular rheumatoid arthritis, and the analysis of such metabolic profiles in order to find disturbances in such profiles in a subject which are caused by or correlated with the said diseases or disorders. Such disturbances can be normalised by treatment of the subject with specified compounds, particularly N-(2-chloro-3,4-dimethoxybenzylideneamino) guanidine or an aminoguanidine. | 01-21-2016 |
| 20160100581 | BIOCIDES AND APPARATUS - A biocide is formed by mixing at least one of ammonium sulfamate and ammonium carbamate with an aqueous solution of a hypochlorite oxidant at a molar ratio of ammonium to hypochlorite of at least 1:1. The biocide is useful in treating microbial or biofilm growth, pulp and paper process water, cooling tower water, waste water, reclaimed waste water, sludge, colloidal suspensions, irrigation water or a medium having a reducing capacity. | 04-14-2016 |
| 20160151311 | N,N'-DI-1 NAPHTHYLGUANIDINE HCL (NAGH) AND N,N'-DI-P-NITROPHENYLGUANIDINE HCL (NAD) TREATMENT FOR STROKE AT DELAYED TIMEPOINTS | 06-02-2016 |
